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AbstrAct
background/aims To evaluate intravitreal aflibercept 
versus laser in subgroups of patients with baseline 
Diabetic Retinopathy Severity Scale (DRSS) scores ≤43, 
47, and ≥53 in VIVID-DME and VISTA-DME.
Methods Patients with diabetic macular oedema were 
randomised to receive intravitreal aflibercept 2 mg every 
4 weeks (2q4), intravitreal aflibercept 2 mg every 8 
weeks after five initial monthly doses (2q8), or macular 
laser photocoagulation at baseline with sham injections 
at every visit. These post hoc analyses evaluate outcomes 
based on baseline DRSS scores in patients in the 
integrated dataset. The 2q4 and 2q8 treatment groups 
were also pooled.
results 748 patients had a baseline DRSS score based 
on fundus photographs (≤43, n=301; 47, n=153; ≥53, 
n=294). At week 100, the least squares mean difference 
between treatment groups (effect of intravitreal 
aflibercept above that of laser, adjusting for baseline 
best-corrected visual acuity) was 8.9 (95% CI 5.99 to 
11.81), 9.7 (95% CI 5.54 to 13.91), and 11.0 (95% CI 
7.96 to 14.1) letters in those with baseline DRSS scores 
≤43, 47, and ≥53, respectively. The proportions of 
patients with ≥2 step DRSS score improvement were 
greater in the intravitreal aflibercept group versus laser, 
respectively, for those with baseline DRSS scores of ≤43 
(13% vs 5.9%), 47 (25.8% vs 4.5%), and ≥53 (64.5% 
vs 28.4%).
conclusions Regardless of baseline DRSS score, 
functional outcomes were superior in intravitreal 
aflibercept-treated patients, demonstrating consistent 
treatment benefit across various baseline levels of 
retinopathy.
trial registration numbers NCT01331681 and 
NCT01363440, Post-results.
IntroductIon
Diabetic retinopathy (DR) is the most common 
microvascular complication in patients with 
diabetes mellitus (DM), and is the leading cause of 
blindness in working-age adults.1 2 Diabetic macular 
oedema (DME), which can occur at any stage of 
DR, is a major cause of vision loss in patients with 
DR.1 
Based on the results of recent clinical trials, 
treatment with anti-vascular endothelial growth 
factor (VEGF) agents has increasingly replaced 
laser photocoagulation as the standard of care 
in DME. Several clinical trials have demon-
strated the efficacy and safety of intravitreal 
ranibizumab in the treatment of DME.3–5 Similar 
results were obtained in studies of intravitreal 
bevacizumab6 7; however, bevacizumab is not 
licensed for ophthalmic use. In the VIVID-DME 
and VISTA-DME studies, patients with DME who 
were treated with intravitreal aflibercept mono-
therapy achieved superior visual and anatomical 
outcomes compared with patients who received 
laser monotherapy.8 9 A comparative effective-
ness study conducted by the Diabetic Retinop-
athy Clinical Research Network ( DRCR. net) 
demonstrated statistical significance of intravit-
real aflibercept over ranibizumab or bevacizumab 
in patients with DME at 12 months, the primary 
endpoint of the study, particularly in those with 
a baseline visual acuity of 20/50 or worse.10 At 2 
years, the visual gains achieved with intravitreal 
aflibercept were statistically superior to bevaci-
zumab but the statistical superiority to ranibi-
zumab was no longer evident.11 An area under 
the curve analysis showed that mean change in 
visual acuity over 2 years was greater with intra-
vitreal aflibercept than with bevacizumab or 
ranibizumab.12
The Early Treatment Diabetic Retinopathy 
Study (ETDRS) was a clinical trial sponsored by 
the National Eye Institute in which patients were 
randomised to treatment with early or deferred 
photocoagulation, a study design which allowed 
observation of the natural course of DR in the 
initially untreated eye. The study found that 
severity of intraretinal microvascular abnormal-
ities, haemorrhages and/or microaneurysms, and 
venous beading on fundus photographs were the 
most important factors in predicting the progres-
sion of DR. Based on these findings, the authors 
developed a Diabetic Retinopathy Severity Scale 
(DRSS) that divides DR into 13 levels ranging 
from absence of retinopathy to severe retinop-
athy including vitreous haemorrhage (table 1). 
This scale can be used to describe overall reti-
nopathy severity as well as the change in severity 
over time.13 According to the American Academy 
of Ophthalmology, DRSS scores are associated 
with the risk of developing proliferative DR 
(PDR). The risk of developing early PDR after 
1 year is low (5.4–11.9%) in patients with a 
DRSS score ≤43, moderate (26.3%) in patients 
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with a DRSS score of 47, and high (50.2%) in patients with 
a DRSS score ≥53.14
To the best of our knowledge, no studies have examined the rela-
tionship between baseline DRSS scores and outcomes in patients 
with DME treated with anti-VEGF agents. Here, we report on 
the impact of baseline DRSS scores on functional and anatomical 
outcomes in patients enrolled in the VIVID-DME and VISTA-DME 
studies.
Methods
design
The study design and methods have been published previously.8 9 
Key details are summarised here. VIVID-DME (NCT01331681) 
and VISTA-DME (NCT01363440) were phase 3, randomised, 
double-masked, active-controlled, 148 week trials comparing 
two dosing regimens of intravitreal aflibercept with laser for the 
treatment of DME. The studies were conducted at 127 sites in 
the USA, Europe, Japan, and Australia, and were conducted in 
accordance with the principles of the Declaration of Helsinki 
and International Conference on Harmonisation.
Participants
Adult patients with type 1 or type 2 diabetes mellitus who 
presented with central-involved DME (defined as retinal thick-
ening involving the 1 mm central subfield thickness) were 
included if best-corrected visual acuity (BCVA) was between 73 
and 24 letters (20/40–20/320 Snellen equivalent) in the study 
eye. Only one eye per patient was included.
randomisation and treatment
Patients were randomised 1:1:1 to treatment with intravitreal 
aflibercept 2 mg every 4 weeks (2q4), intravitreal aflibercept 
2 mg every 8 weeks after five initial monthly doses (2q8), or 
macular laser photocoagulation at baseline with sham injections 
at every visit. Eyes in the 2q8 group received sham injections 
on non-treatment visits. From week 24, additional active treat-
ment (laser in the intravitreal aflibercept groups and intravitreal 
aflibercept in the laser group) was allowed in the case of disease 
recurrence/worsening based on prespecified criteria.
outcomes
The primary efficacy endpoint for the VIVID-DME and 
VISTA-DME studies was the change from baseline in BCVA in 
ETDRS letters at week 52.
table 1 ETDRS final retinopathy severity scale (for individual eyes)
Level severity definition
10 DR absent Microaneurysms and other characteristics 
absent
20 Microaneurysms only Microaneurysms definite; other 
characteristics absent
35 Mild NPDR One or more of the following:
• Venous loops ≥D/1
• SE, IRMA, or VB=Q
• Retinal haemorrhages present
• HE ≥D/1
• SE ≥D/1
43 Moderate NPDR H/Ma=M/4–5 — S/1 or IRMA=D/1–3 (not 
both)
47 Moderately severe NPDR Both L43 characteristics and/or 1 (only) of 
the following:
• IRMA=D4–5
• H/Ma=S/2–3
• VB=D/1
53 Severe NPDR One or more of the following:
• ≥2 of the 3 L47 characteristics
• H/Ma ≥S/4–5
• IRMA ≥M/1
• VB ≥D/2–3
61 Mild PDR FPD or FPE present with NVD and NVE 
absent; or NVE=D
65 Moderate PDR Either of the following:
• NVE ≥M/1 or NVD=D and VH or PRH=A or 
Q
•VH or PRH=D and NVE <M/1 and NVD 
absent
71 High-risk PDR Any of the following:
• VH or PRH ≥M/1
• NVE ≥M/1 and VH or PRH ≥D/1
• NVD=2 and VH or PRH ≥D/1
• NVD ≥M
75 High-risk PDR NVD ≥M and VH or PRH ≥D/1
81 Advanced PDR: fundus 
partially obscured, centre of 
macula attached
NVD=cannot grade, or NVD <D and 
NVE=cannot grade in ≥1 field and absent in 
all others; and retinal detachment at centre 
of macula <D
85 Advanced PDR: posterior 
fundus obscured, or centre of 
macula detached
VH=VS in fields 1 and 2; or retinal 
detachment at centre of macula=D
90 Cannot grade, even 
sufficiently for level 81 or 85
Severity categories for characteristics graded in multiple fields are of the 
form ‘maximum severity/extent’, where maximum severity can be absent (A), 
questionable (Q), definitely present (D), moderate (M), severe (S), or very severe 
(VS), and extent is the number of fields at that severity level. For example, M/2–3 
means that there are two or three fields from fields 3 to 7 with moderate severity, 
and none with higher severity.
ETDRS, Early Treatment Diabetic Retinopathy Study; DR, diabetic retinopathy; FPD, 
fibrous proliferations disc; FPE, fibrous proliferations elsewhere; HE, hard 
exudates; H/Ma, haemorrhages/microaneurysms; IRMA, intraretinal microvascular 
abnormalities; NPDR, non-proliferative DR; NVD, new vessels disc (within one 
disc diameter of disc margin); NVE, new vessels elsewhere (>1 disc diameter from 
disc); PDR, proliferative DR; SE, soft exudates; VB, venous beading; VH, vitreous 
haemorrhage; PRH, preretinal haemorrhage.
table 2 Baseline demographics and disease characteristics by 
baseline DRSS score
Low risk (≤43)
n=301
Moderate risk (47)
n=153
high risk (≥53)
n=294
Laser
Intravitreal 
aflibercept Laser
Intravitreal 
aflibercept Laser
Intravitreal 
aflibercept
Age, years 64.9 
(7.7)
64.9 (9.2) 63.7 
(8.3)
63.8 (8.9) 59.4 
(9.2)
60.0 (9.6)
Duration 
of 
diabetes, 
years
18.5 
(9.7)
18.3 (11.2) 16.5 
(10.0)
16.3 (9.4) 14.3 
(9.2)
13.5 (8.9)
HbA1c, % 7.40 
(1.2)
7.86 (1.5) 7.71 
(1.4)
7.75 (1.7) 7.83 
(1.9)
7.83 (1.5)
BCVA, 
ETDRS 
letters
60.6 
(10.8)
60.5 (9.7) 62.3 
(9.6)
62.4 (9.6) 58.5 
(11.7)
57.2 (11.5)
CRT, µm 487 
(141.2)
472.3 
(136.1)
488.6 
(149.5)
469.3 
(122.0)
541.4 
(168.3)
535.2 (177.3)
Data presented as mean (SD).
Only those with gradable baseline DRSS score are included.
BCVA, best-corrected visual acuity; CRT, central retinal thickness; DRSS, Diabetic 
Retinopathy Severity Scale; ETRDS, Early Treatment Diabetic Retinopathy 
Study; HbA1c, glycated haemoglobin A1c.
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Here we report on the impact of baseline DRSS score (low risk 
(≤43), moderate risk (47), and high risk (≥53)) on outcomes 
for patients enrolled in VIVID-DME and VISTA-DME. Colour 
fundus photography was performed at baseline, week 24, week 
52, week 72 (VISTA-DME) or week 76 (VIVID-DME), and 
week 100. Images were evaluated by masked graders at inde-
pendent reading centres. Fundus images were evaluated by the 
Vienna Reading Centre, Vienna, Austria (VIVID-DME) and the 
Digital Angiography Reading Centre, Great Neck, New York, 
USA (VISTA-DME). Images for 114 patients were categorised 
as ‘ungradable.’ The remaining patients were stratified into 
three subgroups based on baseline DRSS score: low risk (≤43), 
moderate risk (47), and high risk (≥53).
For these post hoc analyses, data from VIVID-DME and 
VISTA-DME have been integrated. Results of statistical analyses 
are presented for pooled intravitreal aflibercept and laser treat-
ment arms.
statistics
Patients included in the efficacy analyses are those from the full 
analysis set (FAS) in both studies (VIVID-DME and VISTA-DME), 
which includes all randomised patients who received any study 
medication and had at least one baseline and one postbaseline 
assessment. The FAS was analysed as randomised. Baseline DRSS 
scores were stratified into three subgroups: low risk (≤43), 
moderate risk (47), and high risk (≥53). Patients without baseline 
DRSS scores (missing or ‘ungradable’ cases as mentioned above) 
were not included in the analyses. For continuous endpoints 
such as change from baseline BCVA, an analysis of covariance 
model was fitted with baseline BCVA, baseline DRSS subgroup, 
treatment group, study, and the interaction between baseline 
DRSS subgroup and treatment as the fixed effect. Nominal p 
values were presented in these ad hoc analyses without further 
multiplicity adjustment. For binary endpoints, such as propor-
tion of patients who gained or lost ≥15 letters, the counts and 
percentages were calculated for each treatment group.
Missing values in the outcomes were imputed using the last 
observation carried forward method, and for eyes that received 
additional treatment, the last value before additional treatment 
was used for analyses.
Patients included in the safety analyses are those from the 
safety population in both studies, which includes all randomised 
patients who received any study treatment.
resuLts
At baseline, among those with baseline DRSS scores (n=748), 
the proportions of patients with DRSS scores of low risk (≤43), 
moderate risk (47), and high risk (≥53) were 38.7%, 20.6%, 
and 40.7%, respectively, in the pooled intravitreal aflibercept 
group and 43.4%, 20.1%, and 36.5% in the laser group. Base-
line demographics and disease characteristics based on baseline 
DRSS scores are reported in table 2. On average, patients in 
the high-risk group were younger, with a shorter duration of 
diabetes, and had worse BCVA and thicker retinas at baseline. 
Haemoglobin A1c levels at baseline were similar across the three 
risk groups.
At both week 52 and week 100, unadjusted mean gains in 
BCVA were greater in patients in all baseline DRSS score 
subgroups treated with intravitreal aflibercept compared with 
laser-treated patients (table 3). An analysis of the least squares 
mean difference between treatment groups (adjusting for base-
line BCVA) showed that, at both time points, the difference 
in treatment effect between intravitreal aflibercept and laser 
had some numerical increasing trend as baseline DRSS score 
increased, from 8.9 (95% CI 5.99 to 11.81), 9.7 (95% CI 5.54 
to 13.91), and 11.0  (95% CI 7.96 to 14.1) letters in those with 
baseline DRSS scores ≤43, 47, and ≥53, respectively(figure 1). . 
At both week 52 and week 100, a greater proportion of 
patients in all baseline DRSS score subgroups treated with 
intravitreal aflibercept achieved a ≥2 step improvement in 
table 3 Unadjusted mean (SD) change in BCVA by baseline DRSS 
score at week 52 and week 100
Week 52 Week 100
Laser
(n=249)
Intravitreal 
aflibercept
(n=499)
Laser
(n=249)
Intravitreal 
aflibercept
(n=499)
Low risk
(DRSS ≤43)
1.3 (11.2) 10.3 (8.7) 1.3 (11.6) 10.2 (10.7)
Moderate risk
(DRSS =47)
0.0 (12.7) 10.0 (6.7) 0.5 (14.5) 10.2 (10.5)
High risk
(DRSS ≥53)
0.5 (11.3) 12.8 (9.5) 0.9 (12.9) 12.1 (12.7)
Only those with gradable baseline DRSS scores are included.
BCVA, best-corrected visual acuity; DRSS, Diabetic Retinopathy Severity Scale.
Figure 1 Difference in treatment effect between intravitreal aflibercept and laser (ETDRS letters), adjusting for baseline BCVA at (A) week 52 and 
(B) week 100. BCVA, best-corrected visual acuity; DRSS, Diabetic Retinopathy Severity Scale; ETDRS, Early Treatment Diabetic Retinopathy Study.
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DRSS score compared with laser-treated patients. Regardless 
of the treatment group, a greater proportion of patients in the 
high-risk group had a ≥2 step improvement compared with 
patients in the medium-risk and low-risk groups (figure 2A 
and B).
Similarly, at both week 52 and week 100, a greater proportion 
of patients in all baseline DRSS score subgroups treated with 
intravitreal aflibercept gained ≥15 letters in BCVA compared 
with laser-treated patients. Regardless of treatment group, a 
greater proportion of patients in the high-risk group gained ≥15 
letters compared with patients in the medium-risk and low-risk 
groups (figure 2C and D).
At both week 52 and week 100, the proportion of patients in 
all baseline DRSS score subgroups who lost >0 letters in BCVA 
was greater in laser-treated patients compared with those treated 
with intravitreal aflibercept. There was no discernible pattern 
based on baseline DRSS score regarding loss of >0 letters in 
BCVA (figure 2E and F).
dIscussIon
In this analysis, we evaluated the impact of baseline 
DRSS scores in patients enrolled in the VIVID-DME and 
VISTA-DME studies. Patients from these studies were 
grouped according to baseline DRSS score (which is asso-
ciated with low, medium, or high risk of developing PDR), 
and mean changes in BCVA were evaluated for each of the 
subgroups. Previous studies have examined the impact of 
baseline characteristics such as central retinal thickness15 16 
and BCVA17 on visual outcomes in patients with DME treated 
with anti-VEGF therapy. To the best of our knowledge, the 
role of baseline DRSS score on visual outcomes in such 
patients has not been evaluated.
The week 52 and week 100 results showed that, compared 
with laser, visual outcomes were superior in the intravitreal 
Figure 2 Proportion of patients (A) with ≥2 step improvement in DRSS score by baseline DRSS score at week 52, (B) with ≥2 step improvement in 
DRSS score by baseline DRSS score at week 100, (C) who gained ≥15 letters in BCVA by baseline DRSS score at week 52, (D) who gained ≥15 letters 
in BCVA by baseline DRSS score at week 100, (E) who lost >0 letters in BCVA by baseline DRSS score at week 52, and (F) who lost >0 letters in BCVA 
by baseline DRSS score at week 100. BCVA, best-corrected visual acuity; DRSS, Diabetic Retinopathy Severity Scale.
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aflibercept groups, regardless of baseline DRSS score. In all 
subgroups, the mean change in BCVA at both time points 
was greater in intravitreal aflibercept-treated eyes compared 
with laser-treated eyes. Irrespective of baseline DRSS score 
(and, therefore, risk of developing PDR), the proportion of 
patients who gained ≥15 letters in BCVA was greater for 
those treated with intravitreal aflibercept than with laser, 
while the proportion of patients who lost >0 letters in 
BCVA was greater in those treated with laser. These find-
ings suggest that among patients with DME, even those 
with more advanced DR at baseline and a greater risk of 
developing PDR within 1 year, greater visual benefits were 
observed with intravitreal aflibercept compared with laser.
The magnitude of functional improvement with intravit-
real aflibercept treatment was similar across baseline DRSS 
risk groups; however, there was a numerical increasing trend 
in treatment difference compared with laser as baseline 
DRSS score increased from low to high. There is a substan-
tial amount of evidence showing that worse baseline visual 
acuity results in greater improvements in patients treated 
with anti-VEGF therapy17–19; however, in the current study, 
the numerical increasing trend was still observed after 
adjustments for baseline visual acuity. This finding suggests 
a real difference in treatment effect based on baseline DRSS 
score, although this analysis was not sufficiently powered to 
show this definitively.
Anatomical outcomes were also superior with intravit-
real aflibercept, with ≥2 step improvements in DRSS score 
occurring in a greater proportion of patients treated with 
intravitreal aflibercept compared with laser, regardless of 
baseline DRSS score. At both time points, ≥2 step DRSS 
improvement was greater in the subgroup of patients with 
baseline DRSS score ≥53 compared with the other baseline 
DRSS score subgroups.
Strengths of the present study include the use of masked 
graders from two reading centres to evaluate fundus photo-
graphs and determine baseline DRSS scores, as well as the fixed 
dosing and strict protocols. However, although VIVID-DME 
and VISTA-DME were well-designed randomised clinical trials, 
this article reports findings from an exploratory post hoc anal-
ysis, and further prospective research is needed to confirm the 
current findings.
In conclusion, these post hoc analyses through week 100 
demonstrate the benefits of intravitreal aflibercept over laser in 
patients with DME regardless of baseline DR severity, suggesting 
that even patients with severe DR can experience visual and 
anatomical improvements after treatment with intravitreal 
aflibercept.
Acknowledgements Medical writing assistance was provided by Corey Eagan, 
MPH, of PAREXEL, and funded by Bayer.
contributors All authors meet the ICMJE criteria for authorship.
Funding The VIVID-DME and VISTA-DME studies were supported by Bayer and 
Regeneron Pharmaceuticals, Inc.
competing interests GS is a consultant to Novartis, Bayer, Allergan, Genentech, 
Roche, Heidelberg Engineering, and Alcon. He has also received support for travel 
to meetings from Bayer HealthCare, Centervue, Heidelberg Engineering, and 
Novartis. He has received payment for lectures from Zeiss, and is a patent holder in 
conjunction with Ocular Instruments, Inc. He has received payment for development 
of educational presentations for Roche. NF is a consultant to Alimera, and has 
received funding from Novartis, Allergan, Alimera, Bayer, and Heidelberg Engineering. 
JJA is a member of advisory boards for Novartis, Bayer, and Allergan. She has 
received personal fees and others from Novartis and others from Bayer. TA Katz is an 
employee of Bayer. CM is an employee of Bayer. CL is an employee of Bayer. FGH is 
a consultant to Acucela, Genentech/Roche, Novartis, Bayer, Alcon, OPTOS, Heidelberg 
Engineering, Carl Zeiss Meditec, Allergan, and Pfizer, and has received financial 
support from OPTOS, Heidelberg Engineering, Carl Zeiss Meditec, Alcon, Genentech/
Roche, Bayer, and Novartis.
ethics approval Institutional Review Board/Ethic Committee approval was 
obtained at each site before the start of the studies.
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work 
is properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2017. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
RefeRenCes
 1 Boyer DS, Hopkins JJ, Sorof J, et al. Anti-vascular endothelial growth factor therapy for 
diabetic macular edema. Ther Adv Endocrinol Metab 2013;4:151–69.
 2 International Diabetes Federation IDF Diabetes Atlas. International diabetes federation 
website. http://www. idf. org/ diabetesatlas (accessed 19 Jan 2017).
 3 Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular 
edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 
2012;119:789–801.
 4 Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema 
with prompt versus deferred laser treatment: three-year randomized trial results. 
Ophthalmology 2012;119:2312–8.
 5 Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized 
ranibizumab treatment in patients with diabetic macular edema: the RESTORE 
extension study. Ophthalmology 2014;121:1045–53.
 6 Nepomuceno AB, Takaki E, Paes de Almeida FP, et al. A prospective randomized trial of 
intravitreal bevacizumab versus ranibizumab for the management of diabetic macular 
edema. Am J Ophthalmol 2013;156:502–10.
 7 Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled 
trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of 
diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 2012;130:972–9.
 8 Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic 
macular edema. Ophthalmology 2014;121:2247–54.
 9 Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic 
macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 
2015;122:2044–52.
 10 Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab for 
diabetic macular edema. N Engl J Med 2015;372:1193–203.
 11 Wells JA, Glassman AR, Ayala AR, et al. Aflibercept, bevacizumab, or ranibizumab 
for diabetic macular edema: two-year results from a comparative effectiveness 
randomized clinical trial. Ophthalmology 2016;123:1351–9.
 12 Jampol LM, Glassman AR, Bressler NM, et al. Anti-vascular endothelial growth factor 
comparative effectiveness trial for diabetic macular edema: additional efficacy post 
hoc analyses of a randomized clinical trial. JAMA Ophthalmol 2016;134.
 13 Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic 
risk factors for progression of diabetic retinopathy. ETDRS report number 12. 
Ophthalmology 1991;98(5 Suppl):823–33.
 14 American Academy of Ophthalmology. International Clinical Diabetic Retinopathy 
Disease Severity Scale detailed table. International Council of Ophthalmology website. 
http://www. icoph. org/ dynamic/ attachments/ resources/ diabetic- retinopathy- detail. pdf 
(accessed 20 Jan 2017).
 15 Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab 
monotherapy or combined with laser versus laser monotherapy for diabetic macular 
edema. Ophthalmology 2011;118:615–25.
 16 Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus 
prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular 
edema. Ophthalmology 2010;117:1064–77.
 17 Chong V, Mitchell P. Baseline predictors of 3-year responses to ranibizumab and laser 
photocoagulation therapy in patients with visual impairment due to diabetic macular 
edema (DME). Eur J Ophthalmol 2013;23:446–62.
 18 Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes 
with ranibizumab or bevacizumab for neovascular age-related macular degeneration. 
Ophthalmology 2013;120:122–9.
 19 Finger RP, Wickremasinghe SS, Baird PN, et al. Predictors of anti-VEGF treatment 
response in neovascular age-related macular degeneration. Surv Ophthalmol 
2014;59:1–18.
group.bmj.com on March 8, 2018 - Published by http://bjo.bmj.com/Downloaded from 
the VIVID-DME and VISTA-DME studies
Severity Scale scores on visual outcomes in 
Impact of baseline Diabetic Retinopathy
Carola Metzig, Chengxing Lu and Frank G Holz
Giovanni Staurenghi, Nicolas Feltgen, Jennifer J Arnold, Todd A Katz,
 published online October 19, 2017Br J Ophthalmol
 4
http://bjo.bmj.com/content/early/2017/10/19/bjophthalmol-2017-31066
Updated information and services can be found at: 
These include:
References
 4#ref-list-1
http://bjo.bmj.com/content/early/2017/10/19/bjophthalmol-2017-31066
This article cites 16 articles, 0 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (289)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on March 8, 2018 - Published by http://bjo.bmj.com/Downloaded from 
